Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Maintains AlloVir(ALVR.US) With Sell Rating, Maintains Target Price $0.5
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
AlloVir | 10-Q: Q2 2024 Earnings Report
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Cytomegalovirus Infection Therapeutics Research 2024: Comprehensive Insights About 15+ Companies and 20+ Pipeline Drugs Featuring Vir, SpyBiotech, Moderna, VBI, Trellis Bioscience, GSK, & AlloVir
AlloVir Finalizes $7 Million Lease Termination Deal
Express News | Allovir Inc: On July 1, Entered Into a Termination Agreement With BP Bay Colony LLC
Express News | Allovir Inc - on June 5 Entered Into a Termination of Sublease Agreement With Amag Pharmaceuticals, Inc
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
AlloVir | 10-Q: Q1 2024 Earnings Report
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
AlloVir(ALVR.US) Officer Sells US$7,493.92 in Common Stocks
Top 4 Health Care Stocks That May Rocket Higher In Q1
AlloVir To Cut 95% of Workforce After Discontinuing Trials
On January 1, 2024, AlloVir Board Approved Reduction Its Workforce By Approximately 95% Of Current Employee Base To Reduce Costs And Preserve Capital - Filing
AlloVir(ALVR.US) Officer Sells US$20,837.56 in Common Stocks
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)